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Renal Norepinephrine Reduction Following Radiofrequency Renal Denervation
Correlates with Extent of Nerve Ablation: Roles of Ablation Areas, Anatomy,
and Number of Treatments
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Anna-Maria Spognardi3, James Stanley3, Debby Highsmith4, Patrick O’Fallon4,
Elazer Edelman5
1CBSET Inc., Lexington, MA, 2Saarland University Hospital, Homburg/Saar,
Germany, 3CBSET, Inc., Lexington, MA, 4Cordis/Biosense Webster, Inc. a Johnson &
Johnson Company, Irwindale, CA, 5Harvard-MIT Biomedical Engineering Center,
Cambridge, Massachusetts
Background: Renal denervation is a treatment option for resistant hypertension.
Preclinical models that explain the dependence of efﬁcacy on treatment parameters
can help differentiate and optimize device efﬁcacy.
Methods: A total of 150 porcine renal arteries were treated with an irrigated multi-
electrode helical catheter (Biosense Webster, CA). Between 2-5 electrodes were
activated for 30-60 sec with power set points ranging from 6-20 W. Renal norepi-
nephrine (NEPI) was measured 7 days post treatment and correlated with morphologic
and morphometric assessments of treated sections. Measured nerve distributions and
ablation areas informed a computational model for predicting the percentage of
affected nerves (AN).
Results: NEPI levels across the range of treatment parameters exhibited a threshold-
like, dependence on %AN, remaining in the range of control levels (360 ng/g) up to
AN¼35% and dropping by 50% and 75% as AN increased to 52% and 70%,
respectively. For 15W/30sec treatments, both NEPI and nerve effects tracked with
number of activated electrodes (statistically signiﬁcant for 5 vs 2 electrodes).
Threshold (w50%) nerve and NEPI effects were only attained when 4 electrodes
were powered. Average %AN increased with total ablation area as predicted by the
computational model when accounting for the (average) measured non-uniform radial
nerve distribution, but assuming that electrode-induced ablation areas achieved are
mutually independent and predictable. Deviations from model-predicted %AN
correlated variable nerve locations and sizes and/or deviant ablation areas. In partic-
ular, aberrantly low ablation areas were observed when electrode treatments were
directed at neighboring blood vessels.
Conclusions: Variable ablation effects can be explained by the conﬂuence of variable
nerve locations and sizes and variable ablation shapes. The additive biomarker effects
seen with angularly staggered treatments can be leveraged to optimize device design
(e.g. electrode number and spacing) and treatment protocols (e.g. catheter rotation
between two consecutive treatments) in the face of unknown variable micro-anatomy.
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Peripheral Endothelial Function and Sympathetic Inﬂuence on Dermal
Microcirculation Correlate with Long-Term Blood Pressure Response in Renal
Denervation Patients
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Thomas Munzel1, Tommaso Gori1, Ulrich Hink1
1University of Mainz Medical Center, Mainz, Germany
Background: Renal denervation (RDN) has emerged as an interventional treatment
option for treatment-resistant hypertension. Hypertensive patients are often charac-
terized by an increased sympathetic tone as well as impaired endothelial function.
However, there is a paucity of diagnostic tools to identify those hypertensive patients
that will beneﬁt from RDN (responders), and to proof successful RDN application. We
therefore aimed to investigate the effects of RDN on vascular reactivity and sympa-
thetic vascular response, with the ultimate goal to establish potential markers of
therapeutic success.
Methods: In 23 patients (mean age 64 years, 13 men, mean ambulatory blood pres-
sure monitoring (ABPM) 148/83 mmHg;  3 (mean 4.78) antihypertensive drugs in
adequate dosage and combination) that underwent RDN (Medtronic Symplicity
(n¼16), St. Jude Medical EnligHTN (n¼7)), ﬂow-mediated dilation (FMD) and low
ﬂow-mediated constriction (L-FMC) as non-invasive measures of endothelial function
were assessed. Sympathetic component to vasomotor function in dermal microcircu-
lation was determined by laser Doppler ﬂowmetry.
Results: 13/23 (57%) of the patients showed an ABMP reduction  5mmHg at
6 months and hence were considered RDN-responders. Responders had a mean
ABPM reduction of -21/-6 mmHg as compared to baseline (p  0.003). In these
patients, L-FMC was found to be signiﬁcantly reduced (-2.54 to -4.02, p  0.017), andJACC Vol 64/11/Suppl B j September 13–17, 2014 j TCT Abstracts/Hysympathetic inﬂuence on vascular tone was reduced from 54 to 50 % (p  0.037),
while non-responders did not show any signiﬁcant differences.
Conclusions: Non-invasive endothelial and sympathetic functional assessment pa-
rameters correlate with successful blood pressure reduction responses to renal
denervation in patients with treatment-resistant hypertension. Further and larger scale
studies are necessary to analyze the potential predictive utility of these parameters in
the clinical RDN setting, in particular with regard to optimized patient selection for the
procedure.
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First Clinical Experience with Neurotropic Agents for Treatment of Sympathetic
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Background: New device-based solutions to treat hypertension are focused on the
overactive sympathetic nervous system as the therapeutic target. Early results from
electrical stimulation of carotid baroreceptors and energy-based (radiofrequency, ul-
trasound) ablation of renal nerves have shown the ability to reduce blood pressure.
Methods: We investigated a simple, catheter-based approach of delivering neuro-
tropic agents near renal nerves, speciﬁcally targeting nerve axons, to interfere with
sympathetic nerve function. A small volume of NW2013 (proprietary formulation
developed by Northwind Medical, San Jose, CA), was injected into renal artery walls
using an endovascular catheter with microneedles.
Results: Seven (7) patients were technically successfully treated through local
administration of NW2013 near renal nerves. There were no serious procedure-related,
device-related or agent-related complications. Injury to the renal artery wall was
minimal with no spasm, dissections or vessel perforations. Mild to moderate pain was
reported during agent injection, which was managed by 5mg of morphine, and was
signiﬁcantly less compared to energy-based therapies. Five (5) patients completed
their 1-month and 3-month follow ups and were included in the analysis. Mean
systolic/diastolic ofﬁce blood pressure (OBP) and 24-hour ambulatory blood pressure
(ABP) at baseline were 181/92 and 164/105 mm of Hg, respectively. At 1 and
3 months after treatment, the average OBP reduction was 33/8 and 45/8 mm of Hg,
respectively; equivalent ABP decrease was 12/13 and 22/16 mm of Hg. These results
are very promising and demonstrate that treatment of sympathetic hypertension pa-
tients using local delivery of neurotropic agents is safe and feasible. In addition, the
therapy offers advantages over energy-based methods in terms of nerve speciﬁcity,
less pain and cost effectiveness.
Conclusions: Local administration of selective neurotropic agents surrounding renal
arteries seems to be a safe and feasible procedure to treat sympathetic hypertension.
Long-term data from randomized clinical studies are needed to further evaluate efﬁ-
cacy and durability of this procedure.
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Background: SYMPLICITY HTN-3 was a randomized, blinded, sham-controlled
trial of renal denervation (RDN) in patients with resistant hypertension that demon-
strated safety but not efﬁcacy of RDN. Results for the prespeciﬁed African-American
(AA) and non-African American (non-AA) subgroups are presented.
Methods: All patients were required to have an ofﬁce systolic blood pressure (SBP)
160 mm Hg and an ambulatory 24-hour SBP 135 mm Hg while taking 3 anti-
hypertensive drugs at maximally-tolerated dose, including a diuretic. Baseline clinical
and procedural characteristics, baseline and 6-month antihypertensive medication use
and changes in ofﬁce and ambulatory blood pressure were compared between groups.
Results: AA patients comprised (26.2%) of the cohort in this trial. AA were
younger, included more females, had a lower incidence of coronary artery disease
and had a greater incidence of asthma, stroke and heart failure than non-AA patients.
Change in ofﬁce and ambulatory BP measurements are shown in the table. Dif-
ferences in Ofﬁce SBP reduction at 6 months were not apparent at earlier time
points. The use of vasodilators (majority hydralazine) was greater in the AA than the
non-AA subgroup (47% vs 34%, p¼0.03 for RDN patients and 56% vs 41%,
p¼0.09 for sham patients). The SBP decrease in the AA sham group on vasodilators
was -21.9 mm Hg and -12.7 mm Hg in the AA cohort not on vasodilators (p¼0.276;
p for interaction ¼0.185).pertension Therapies Including Renal Denervation B119
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subgroup may be due to greater BP reductions in the AA sham control group. This
greater than expected drop in BP in the sham control group suggests a post-
randomization interaction with an exposure that impacted BP lowering. Further























180.6  16.4 183.9  19.8 0.294 179.5  16.0 178.6  15.3 0.611
3 month
change
-16.0  22.0 -13.7  21.8 0.546 -15.5  24.5 -14.6  22.4 0.710
6 month
change
-15.5  25.4 -17.8  29.2 0.641 -15.2  23.5 -8.6  24.8 0.012
DBP
Baseline
101.1  17.0 104.4  16.5 0.264 95.0  16.2 96.6  14.9 0.368
3 month
change
-8.3  11.9 -4.9  11.6 0.114 -6.9  12.0 -4.5  11.1 0.067
6 month
change
-8.2  12.1 -6.8  17.1 0.631 -6.0  11.8 -3.7  11.8 0.086
ABPM
SBP Baseline 160.4  13.8 162.7  16.2 0.384 158.7  13.0 158.2  14.8 0.729
6 month
change
-7.6  16.3 -6.7  18.4 0.782 -6.5  14.8 -4.0  16.8 0.158
DBP
Baseline
92.7  14.6 95.3  13.2 0.308 86.6  13.4 89.1  14.6 0.094
6 month
change
-4.8  9.9 -3.6  11.6 0.542 -3.89  9.0 -2.9  9.5 0.337TCT-406
Renal Artery Trauma Induced By Four Different Renal Denervation Systems.
A Multi-Modality Intra-Arterial Imaging Study
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Joost Daemen8
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Hamburg, 6Erasmus University Medical Center, Rotterdam, Netherlands,
7Thoraxcenter, Rotterdam, Netherlands, 8Erasmus MC - Thoraxcenter, Rotterdam,
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Background: Renal denervation is a new treatment for resistant hypertension. As new
systems are introduced, the incidence of acute renal artery wall injury with relation to
the denervation method is unknown. We aimed to investigate by quantitative angi-
ography, intravascular ultrasound (IVUS) and optical coherence tomography (OCT),
the acute repercussion of renal denervation for treatment of resistant hypertension on
the renal arteries treated with 4 different systems.
Methods: Nineteen patients underwent bilateral renal denervation in two centers with
4 different systems: Symplicity (n¼6), Paradise (n¼5), Oneshot (n¼6) and
Vessix V2 (n¼2). Analysis included quantitative angiography pre- and post-
procedure, morphometric measurements by IVUS pre- and post-procedure, and assess-
ment of vascular trauma (dissection, oedema, or thrombus) by OCT after denervation.
Results: No signiﬁcant differences between pre- and post-procedure were observed in
lumen and vessel dimensions by quantitative angiography or IVUS. By post-
denervation OCT, dissection was seen in 12 arteries (37.5%), 11 of which were treated
with balloon-based denervation catheters. Thrombus and oedema were detected in 26
(81.2%) and 22 arteries (68.8%), respectively. In arteries with any dissection by OCT
the balloon-to-artery ratio was higher (1.240.13 versus 1.100.11, p¼0.01), while
6 out of 7 arteries (86%) treated with balloon catheters with a balloon-to-artery
ratio>1.18 had evidence of dissection by OCT. In arteries with lumen contour
irregularities or dissection by angiography there was higher incidence of dissection
and a trend for higher thrombus (dissection: 66.7% versus 15.8%, p< 0.01; thrombus:
100.0% versus 68.4%, p¼0.06).
Conclusions: A varying extent of vascular injury was observed after renal denervation
in all systems. Dissections were observed mainly in arteries treated with balloon-based
denervation catheters and were associated with a higher balloon-to-artery ratio and
vessel wall irregularities on post-procedural angiogram.
TCT-407
Evaluation of the Acute and Long Term Renal Artery Re-Innervation Attempt
Response Following Catheter-Based Renal Denervation in a Swine Model: An
Immunohistochemical Characterization
Serge D. Rousselle1, Randy Hart1, Joan Wicks1, Armando Tellez1
1Alizée Pathology, Thurmont, MD
Background: Catheter-based renal denervation (RDN) emerged as a therapeutic
option fo r resistant hypertension patients. Nerve “regrowth” has been questioned. We
aimed to characterize the renal nerve response following RDN acutely and long term.B120 JACC Vol 64/11/Suppl B j September 13–17, 2014Methods: Swine underwent bilateral RDN and followed for 7, 30, and 180 days.
A representative section of each time point was selected for H&E and immunohis-
tochemical (IHC) analysis. IHC consisted on S100 (Schwann cell), Tyrosine hy-
droxylase (TH; efferent motor renal nerves), calcitonin gene-related peptide (CGRP)
and substance P (SP); (CGRP and SP afferent sensory renal nerves).
Results: H&E displayed the typical acute (7 days: nerve necrosis, distal atrophy) and
chronic (180 days: nerve ﬁbrosis) nerve injury. At 180 days we could observe evi-
dence of nerve remodeling and tentative regeneration, morphological recovery of
S100, and TH staining and to variable degrees of CGRP and SP staining. However,
there was evidence of TH and S100 staining spill over and extension of neural bundles
within and across the thickened perineurium, forming neuroﬁbrous tangles highly
reminiscent of amputation neuromas (neuromatous regeneration). IHC revealed that
the nerve displayed early signs of TH and S100 positive ﬁbers within and beyond the
ﬁbrous perineurium as early as 7 days following RDN. This perineurial neuromatous
proliferation becomes more evident at longer time points. At 180 days, these neu-
romatous tangles became very prominent with affected nerves completely remodeled
into neuromatous proliferative bundles.
Conclusions: It has been previously demonstrated in renal transplant models that
sympathetic nerves have the ability to regenerate. Furthermore,there are evident signs
of increased nerve count in swine model at longer time points following RDN.
However this is the ﬁrst evidence that this “regenerative nerve attempt” occurs as early
as 7 days following RDN therapy and is progressively increasing over time, resulting
in the formation of poorly organized tangles of nerve ﬁbers, Schwann cells and
connective tissue. This is the ﬁrst complete histological characterization of neu-
romatous nerve regrowth following RDN.
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Renal Artery Denervation With A New Simultaneous Multielectrode Catheter
For Treatment Of Resistant Hypertension: 12-Month Update From The
SYMPLICITY Spyral First-In-Man Study
Robert J. Whitbourn1, Tony Walton2, Scott Harding3
1Cardiovascular Research Centre, St. Vincent Hospital Melbourne, Melbourne,
Australia, 2Epworth Hospital, Richmond, Australia, 3Wellington Hospital, Wellington,
New Zealand
Background: The SYMPLICITY Spyral ﬁrst-in-man (FIM) study investigated the
safety and effectiveness of the Spyral multielectrode renal denervation catheter to
lower blood pressure in patients with resistant hypertension.
Methods: The prospective, open label Spyral FIM study enrolled 50 subjects with
resistant hypertension deﬁned as an ofﬁce systolic blood pressure of 160 mm Hg
(150 mm Hg for type 2 diabetics) despite adherence to an antihypertensive regimen
of3 drug classes (ideally including a diuretic). Subjects with an estimated glomerular
ﬁltration rate of < 45 mL/min/1.73m2, type 1 diabetes mellitus, renal artery stenosis of
>50%, renal artery aneurysm, and prior renal artery intervention were excluded. The
protocol speciﬁed one denervation treatment per artery via delivery of 4 simultaneous
60 seconds ablations per artery. The safety endpoint is a composite of vascular com-
plications, renal artery reintervention, new onset end stage renal disease, death,
myocardial infarction, signiﬁcant embolic event resulting in end-organ damage, hy-
pertensive crisis and new renal artery stenosis. Effectiveness is measured by change in
ofﬁce BP from baseline at 1, 3, 6, and 12 months and annually thereafter.
Results: The mean age of subjects was 63 years, 64% were men, 46% had type II
diabetes mellitus, and baseline estimated glomerular ﬁltration rate was 85.1 
32.1 mL/min/1.73m2. Baseline systolic and diastolic blood pressure was 181 
17 mm Hg and 95  12 mm Hg, respectively, and the mean number of antihyper-
tensive drug classes was 4.5  1.1. The mean number of ablations per artery was 3.25.
Three access-site pseudoaneurysms and 1 myocardial infarction occurred during
6 months follow-up. No new renal artery stenosis or hypertensive emergencies
occurred, and there was no clinically meaningful change in renal function. The change
in ofﬁce-based blood pressure was -19.9  25.0/-7.3  11.5 mm Hg at 6 months,
p< 0.001.
Conclusions: Renal denervation using the Spyral multielectrode catheter is safe and
results in signiﬁcant reduction of ofﬁce blood pressure from baseline. 12-month
follow-up results will be available for presentation in September.
TCT-409
Preclinical and Early Clinical Experience of a Non-vascular Treatment for
Resistant Hypertension
Richard R. Heuser1, Terry Buelna2, Adam Gold3, Rahul R. Rao3,
William Van Alstine4, Mihir Desai5
1St. Luke’s Medical Center, Phoenix, United States, 2Verve Medical, Santa Barbara,
CA, 3Verve Medical, Peoria, AZ, 4Purdue University, West Lafayette, IN, 5USC
Institute of Urology, Los Angeles, CA
Background: The Symplicity HTN-3 recently failed to meet its primary efﬁcacy
endpoint in blood pressure reduction. The device used in this study as well as all other
denervation systems only ablate peri-arterial nerves. The Verve Medical system di-
rects radiofrequency energy to the renal pelvic space where the preponderance of
afferent nerves originate and are closely accessible. We have previously demonstrated
the feasibility of the Verve Medical NephroBlate to ablate these nerves.
Methods: We developed a protocol to treat a small number of patients (n¼3, 4 kid-
neys) undergoing elective nephrectomy. After submission to the hospital institutional
review board and after patient informed consent we treated three patients with endj TCT Abstracts/Hypertension Therapies Including Renal Denervation
